Mild cognitive impairment and cognitive impairment, no dementia: Part A, concept and diagnosis
Tóm tắt
Mild cognitive impairment (MCI) and cognitive impairment, no dementia (CIND) are controversial emerging terms that encompass the clinical state between elderly normal cognition and dementia. This article reviews recent work on the classification of MCI and CIND, their prognosis, and diagnostic approaches and presents evidence‐based recommendations approved at the meeting of the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD3) held in Montreal in March, 2006. New short tools such as the Montreal Cognitive Assessment are making it easier for family physicians to confidently attach the label of MCI.
Tài liệu tham khảo
10.1016/0197-2456(95)00134-4
10.1016/0895-4356(90)90073-X
CSHA, 2000, The incidence of dementia in Canada: the Canadian Study of Health and Aging Working Group, Neurology, 55, 66, 10.1212/WNL.55.1.66
10.1212/WNL.44.9.1563
McKann G., 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA work group under the auspices of the Department of Health Services Task Force on Alzheimer's disease, Neurology, 34, 939, 10.1212/WNL.34.7.939
10.1080/87565648609540348
10.1080/87565648909540440
10.1111/j.1532-5415.1995.tb05565.x
10.1080/13825589608256617
Salthouse T.A., 1991, Theoretical perspectives on cognitive aging, 438
10.1212/WNL.56.11.1533
10.1093/geronb/51B.4.P217
10.1212/01.wnl.0000219668.47116.e6
10.1076/clin.14.4.504.7200
10.1016/S0140-6736(97)01007-6
10.1001/archneur.1995.00540300086018
10.1001/archneur.60.4.577
10.1159/000071189
10.1176/appi.ajp.159.3.436
10.1111/j.1532-5415.1985.tb07109.x
10.1192/bjp.140.6.566
10.1212/WNL.41.4.469
Reisberg B., 1988, Global Deterioration Scale (GDS), Psychopharmacol Bull, 24, 661
10.1177/089198879901200402
10.1002/1099-1166(200011)15:11<983::AID-GPS238>3.0.CO;2-5
10.1002/gps.930070705
10.1111/j.1532-5415.1993.tb06448.x
10.1017/S1041610294001626
Smith A.D., 1996, Use of structural imaging to study the progression of Alzheimer's disease, Br Med Bull, 52, 3, 10.1093/oxfordjournals.bmb.a011568
10.1001/archneur.56.3.303
10.1212/WNL.56.9.1133
10.1001/jama.1995.03520400044042
10.1111/j.1365-2796.2004.01388.x
10.1212/01.WNL.0000132523.27540.81
Lopez O., 2002, Risk factors for mild cognitive impairment in a population study, Neurology, 58, A238
Chertkow H., 1998, Mild memory loss in the elderly: can we predict development in dementia?, Can J Neurol Sci, 25, 1
10.1159/000078504
10.1111/j.1365-2796.2004.01380.x
H.Chertkow.What are the characteristics of patients with mild cognitive impairment who do not progress to dementia? The American Neurological Association San Francisco CA Oct 212003
H.M.Chertkow A.Duong N.Philips H.Bergman L.Babins N.KelnerMild cognitive impairment the danger of basing the diagnosis on published normative groups (P3‐072) Paper presented at ICAD‐Alzheimer's Association 10th International Conference on Alzheimer's Disease and Related Disorders2006 Madrid Spain
10.1136/jnnp.2005.085332
Grundman M., 1996, ADSC Cooperative Study: rate of dementia of the Alzheimer type (DAT) in subjects with mild cognitive impairment, Neurology, 46, A403
10.1212/01.wnl.0000238517.59286.c5
H.Chertkow L.Verret H.Bergman C.Wolfson R.McKelveyPredicting progression to dementia in elderly subjects with mild cognitive impairment: a multidisciplinary approach Paper presented at 2001 Contemporary Clinical Issues Plenary Session 53rd Annual Meeting American Academy of Neurology2001 Philadelphia PA
10.1192/bjp.168.4.470
10.1001/archneur.58.3.397
10.1212/01.WNL.0000080366.90234.7F
10.1002/(SICI)1099-1166(200005)15:5<434::AID-GPS137>3.0.CO;2-2
10.1212/WNL.56.1.37
10.1016/S0140-6736(99)06155-3
Chertkow H.M., 1998, Standard neuropsychological tests do not predict development of Alzheimer's Disease in indivduals with “Age‐associated Cognitive Decline”, Can J Neurol Sci, 25, S27
Craik F., 1994, Memory changes in normal aging, Curr Dir Psychol Sci, 3, 1558, 10.1111/1467-8721.ep10770653
10.1002/gps.477
10.1111/j.1532-5415.2000.tb04992.x
10.1159/000051284
C.Bouras.Evolution of AD pathology in the aging brain Paper presented at American Academy of Neurology2002 Geneva Switzerland
10.1001/archneur.63.1.38
10.1093/jnen/62.11.1087
Bennett D.A., 2005, Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions, Neurology, 64, 83441, 10.1212/01.WNL.0000152982.47274.9E
10.1001/jama.281.15.1401
S.T.DeKosky M.Ikonomovic E.J.Cochran J.H.Kordower E.J.MufsonCholinergic upregulation in hippocampus in mild cognitive impairment: relation to Alzheimer Neuropathology Paper presented at 54th Annual Meeting of the American Academy of Neurology Denver Colorado April 13‐202002
10.1001/archneur.57.5.675
10.1212/01.WNL.0000089238.07771.C7
Hsiung G.‐Y., 2002, An analysis of vascular risk factors and ApoE genotype in subtypes of dementia in the ACCORD study, Neurology, 58, A107
10.1001/archneur.55.8.1065
10.1212/WNL.54.7.1492
10.1037/0882-7974.13.1.80
10.1159/000017092
Corrada M., 2002, Plasma total cholesterol, LDL, HDL levels and the risk of Alzheimer disease: the Baltimore Longitudinal Study of Aging, Neurology, 58, A106
Yaffe K., 2002, Inflammatory markers and cognitive decline in well‐functioning elders: the Health ABC Study, Neurology, 58, A106
10.1212/WNL.51.4.993
Fox N.C., 2000, Increased rates of atrophy in early and preclinical AD: studies with registration of serial MRI, Neurobiol Aging, 21, S74, 10.1016/S0197-4580(00)82552-X
10.1212/WNL.55.4.484
M.J.deLeon A.Convit.Longitudinal measures of hippocampal formation pathology and CSF measures of phospho‐tau and amyloid beta: early markers for Alzheimer disease Paper presented at Seventh International Geneva/Springfield symposium on advances in Alzheimer Therapy2002 Geneva Switzerland
10.1073/pnas.191044198
10.1056/NEJM199603213341202
McKelvey R., 1999, Lack of prognostic significance of SPECT abnormalities in non‐demented elderly subjects with memory loss, Can J Neurol Sci, 26, 23
10.1212/WNL.50.6.1563
10.1212/WNL.55.2.210
A.Nordberg.PET activation in MCI and AD patients Paper presented at Seventh Annual Springfield/Geneva symposium on advances in Alzheimer Therapy2002 Geneva Switzerland
10.1056/NEJM200008173430701
L.Backman.The cognitive transition from normal aging to AD Paper presented at the Seventh Springfield/Geneva symposium on advances in Alzheimer Therapy2002 Geneva Switzerland
10.1001/archneur.58.3.411
10.1001/archneur.1996.00550050053023
10.1111/j.1532-5415.1997.tb00947.x
10.1176/appi.ajp.157.9.1399
10.1017/S1355617701755105
10.1212/WNL.53.7.1480
10.1212/WNL.54.6.1297
10.1016/S0304-3940(99)00617-5
10.1212/01.WNL.0000147470.58328.50
10.1097/01.wad.0000126613.05674.0c
10.1016/j.cger.2003.10.001
10.1212/WNL.59.2.198
10.1016/S1474-4422(04)00710-0
10.1001/archneur.63.1.15
10.1007/s11910-003-0020-2
Ritchie K., 2004, Mild cognitive impairment: an epidemiological perspective, Dialogues in Clinical Neuroscience, 6, 401, 10.31887/DCNS.2004.6.4/kritchie
10.1212/01.WNL.0000034176.07159.F8
10.1007/978-3-7091-7508-8_4
H.Chertkow.Five year follow‐up of mild cognitive impairment predictors of progression—the 8th International Conference on Alzheimer's Disease and Related Disorders. Stockholm Sweden July2002
10.1002/gps.1049
Petersen R.C., 1999, Mild cognitive impairment: clinical characterization and outcome—correction, Arch Neurol, 56, 6, 10.1001/archneur.56.3.303
10.1046/j.1440-1614.2002.00972.x
10.1097/00019442-200508000-00003
10.1016/S1474-4422(03)00262-X
10.1212/01.WNL.0000134664.80320.92
10.1001/archneur.58.12.1985
Jelic V., 2003, Treatment of mild cognitive impairment: rationale, present and future strategies, Acta Neurol Scand Suppl, 179, 83, 10.1034/j.1600-0404.107.s179.12.x
10.1002/gps.1042
10.1007/s00415-005-0597-2
10.1111/j.1532-5415.2005.53221.x
10.1159/000079198
10.1177/070674370505000110
Xu G., 2004, Cross‐cultural comparison of mild cognitive impairment between China and USA, Curr Alzheimer Res, 1, 55, 10.2174/1567205043480564
10.1080/1360786031000120741
10.1001/archneur.60.12.1777
10.1073/pnas.0501157102
10.1111/j.1532-5415.2005.53269.x
10.1097/00005650-200209000-00007
10.1212/WNL.62.4.556
10.1212/WNL.59.7.1042
10.1034/j.1600-0404.2002.01225.x
10.1006/nimg.2001.0992
10.1017/S0033291703007839
10.1093/brain/awg236
10.1001/archneur.60.10.1385
Farlow M.R., 2004, Impact of APOE in mild cognitive impairment, Neurology, 63, 1898, 10.1212/01.WNL.0000144279.21502.B7
10.1212/01.WNL.0000118301.92105.EE
10.1001/archneur.61.1.59
10.1212/01.WNL.0000144281.38555.E3
10.1080/13554790490896820
10.1001/archneur.62.6.975
Geslani D.M., 2005, Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease, Dement Geriatr Cogn Disord, 19, 383, 10.1159/000084709
10.1159/000082351
10.1111/j.1532-5415.2005.53566.x
10.1136/jnnp.2004.047720
10.1212/01.wnl.0000202520.68987.48